Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Transplants - are mice leading the way?

05.07.2004


A new protocol for bone marrow transplants, which does not require the destruction of the recipient’s immune system before transfer of the new bone marrow, is described by a group of Oxford scientists in the 6th of July issue of the Proceedings of the National Academy of Sciences of the United States of America.

Furthermore, Luis Graça, Alain Le Moine, Herman Waldmann and colleagues from the University of Oxford, UK also found that following bone marrow transplant it is possible to successfully transplant other organs from the same donor, including skin, the most difficult organ to be successfully transplanted, into this now hybrid/chimeric bone marrow recipient.

The number of human tissue transplants is on the increase all over the world. In Europe, hundreds of thousands of tissue transplants are performed each year, while only in 1999 as many as 750 000 people in the United States of America received human tissue, twice as many as in 1990.



Graça, Le Moine and Waldmann’s team have been working with mice for a number of years to find alternative protocols for safer and more effective organ transplantations.

Because the immune system has evolved to react against any foreign intruder while remaining non-responsive against its own body, organs from other individuals are seen as foreign and so potentially dangerous which leads to their rapid destruction by the immune system, the body’s defence mechanism. This creates serious problems in clinical transplantation and until now only the use of strong immunosuppressive drugs permits relative transplantation success. This however is not ideal, not only because rejection frequently occurs but also because these drugs compromise the entire immune system making individuals much more susceptible to infection or cancer.

Graça, Le Moine and colleagues work on an alternative model of tolerance based on the use of antibodies against several proteins found in the cells involved in organ rejection. Although the idea of antibodies is not new, these have been mostly used to delete entire populations of cells involved in the graft rejection process. This has the disadvantage of creating “ holes” in the immune system and, like the immunosuppressive therapies widely used in transplant, increase the recipient/host’s disease susceptibility.

What is interesting about the Oxford’s scientists work is that their antibodies do not seem to kill the host cells involved in organ rejection but instead apparently re-programme these cells rendering them tolerant to the foreign organ while leaving the remaining immune system intact and fully operational. It is this specificity of the treatment, the capacity of only making tolerant the cells specific for the foreign organ while keeping the remaining immune system undamaged, that makes Graça, Le Moine and colleagues’ work so exciting.

However, it is still not clear what the mechanism is behind this organ-specific tolerance and this has created problems to the development of human therapies. In the work now published, Graça, Le Moine and colleagues investigate claims that CD4+CD25+ TCR+ cells, a group of cells of the immune system called this way because they express in their cellular membrane the three proteins: CD4, CD25 and TCR, are capable of regulating specific parts of the immune system without affecting the remaining immune cells and might be the cells responsible for inducing the type of organ transplant tolerance observed after Graça and Le Moine’s antibody therapy.

Unfortunately, the results by the team of scientists do not support the hypothesis. Nevertheless, this is still a very important result as it undoubtedly challenges the wide spread assumption that these cells are main regulators of immune responses.

Furthermore, Graça, Le Moine and colleagues also describe a new protocol for bone marrow transplantation and successfully achieve a skin graft transplant between totally different donors and recipients something never achieved before without immune deletion.

In fact, the team of scientists show how a course of their non-depleting antibodies, which are specific for proteins found on the membrane of the cells involved in graft rejection, when given at the same time as a bone marrow transplant, leads to complete acceptance of this foreign bone marrow. This is extraordinarily important as the normal protocol for bone marrow transplants require at least partial destruction of the recipient immune system so the new bone marrow would not be rejected.

Graça, Le Moine and colleagues also show for the first time that skin from a fully foreign donor is also accepted if this organ is transplanted together with bone marrow cells from the same donor while receiving the team’s set of tolerogenic antibodies.

These results are extremely important first because they describe an alternative and much more effective protocol to control the immune system in bone marrow transplants. Secondly, their new protocol of transferring bone marrow together with the organ to transplant proved much more effective, to such a extent that even a totally foreign skin graft was successful, something which has never been accomplished before in the absence of immunosuppression. In a world where more and more transplants are necessary as result of an increasing aging population this is a critical breakthrough.

Finally, Graça, Moine and colleagues capacity of “ re-programme” the immune system without affecting its whole capacity to fight infection might prove extremely important also in other diseases where pathology results from deregulation of the immune system as it seems to be the case in diabetes, rheumatoid arthritis or multiple sclerosis.

Ana Paula Gravito | alfa
Further information:
http://www.oct.mct.pt

More articles from Life Sciences:

nachricht MicroRNA helps cancer evade immune system
19.09.2017 | Salk Institute

nachricht Ruby: Jacobs University scientists are collaborating in the development of a new type of chocolate
18.09.2017 | Jacobs University Bremen gGmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>